- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
U.S. Pharmaceuticals & Biotech Financially Fit Penny Stocks
Results
74
A Penny Stocks screener, typically smaller or younger companies trading at a price below 5, with a focus on solid financial health that should present companies with a lower risk profile than other early-stage businesses
74 companies
AN2 Therapeutics
Market Cap: US$35.3m
A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
ANTX
US$1.28
7D
-1.2%
1Y
21.4%
Caribou Biosciences
Market Cap: US$173.2m
A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.
CRBU
US$2.13
7D
23.8%
1Y
12.7%
Atea Pharmaceuticals
Market Cap: US$230.1m
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
AVIR
US$2.90
7D
-0.3%
1Y
-15.5%
Nuvation Bio
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
NUVB
US$3.24
7D
-0.6%
1Y
35.6%
Veru
Market Cap: US$49.4m
A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).
VERU
US$3.45
7D
0.9%
1Y
-55.6%
Ventyx Biosciences
Market Cap: US$199.7m
A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.
VTYX
US$2.75
7D
19.0%
1Y
15.1%
Barinthus Biotherapeutics
Market Cap: US$42.8m
A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.
BRNS
US$1.18
7D
10.2%
1Y
-1.8%
Cassava Sciences
Market Cap: US$164.7m
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
SAVA
US$3.26
7D
56.7%
1Y
-89.3%
Century Therapeutics
Market Cap: US$41.9m
A clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
IPSC
US$0.48
7D
-1.5%
1Y
-68.3%
Alto Neuroscience
Market Cap: US$105.1m
Operates as a clinical-stage biopharmaceutical company in the United States.
ANRO
US$3.88
7D
1.6%
1Y
-67.0%
Pyxis Oncology
Market Cap: US$135.8m
A clinical stage company, engages in the development of therapeutics to treat solid tumors.
PYXS
US$2.17
7D
-1.8%
1Y
-38.2%
Kezar Life Sciences
Market Cap: US$28.5m
A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.
KZR
US$3.80
7D
1.6%
1Y
-30.8%
Prelude Therapeutics
Market Cap: US$58.3m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.17
7D
12.5%
1Y
-43.8%
ALX Oncology Holdings
Market Cap: US$67.5m
A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
ALXO
US$1.55
7D
47.6%
1Y
-14.4%
Acumen Pharmaceuticals
Market Cap: US$74.5m
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
ABOS
US$1.27
7D
1.6%
1Y
-45.7%
XBiotech
Market Cap: US$88.7m
A biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases.
XBIT
US$2.78
7D
4.1%
1Y
-57.6%
AbCellera Biologics
Market Cap: US$1.5b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$4.77
7D
4.4%
1Y
95.5%
Ovid Therapeutics
Market Cap: US$89.6m
A biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
OVID
US$1.40
7D
20.7%
1Y
25.0%
Athira Pharma
Market Cap: US$16.6m
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
ATHA
US$4.07
7D
7.7%
1Y
-6.8%
Seer
Market Cap: US$132.2m
A life sciences company, develops and commercializes products to decode the biology of the proteome.
SEER
US$2.25
7D
9.2%
1Y
31.6%
MacroGenics
Market Cap: US$104.9m
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
MGNX
US$1.72
7D
12.4%
1Y
-43.4%
Synlogic
Market Cap: US$20.4m
A biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
SYBX
US$1.70
7D
-0.5%
1Y
12.7%
Cytek Biosciences
Market Cap: US$472.0m
A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
CTKB
US$3.41
7D
-13.0%
1Y
-32.6%
Elite Pharmaceuticals
Market Cap: US$686.8m
A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.
ELTP
US$0.64
7D
-1.8%
1Y
63.7%
Tiziana Life Sciences
Market Cap: US$196.2m
A biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States.
TLSA
US$1.97
7D
18.7%
1Y
109.6%
Inhibitor Therapeutics
Market Cap: US$8.6m
A pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.
INTI
US$0.05
7D
16.0%
1Y
-37.6%
Savara
Market Cap: US$733.2m
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$3.51
7D
-2.5%
1Y
-15.4%
Rapid Micro Biosystems
Market Cap: US$143.7m
A life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally.
RPID
US$3.16
7D
3.6%
1Y
272.9%
Shattuck Labs
Market Cap: US$114.5m
A biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases.
STTK
US$2.35
7D
21.1%
1Y
-35.3%
Genenta Science
Market Cap: US$53.8m
A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
GNTA
US$3.15
7D
1.6%
1Y
-21.3%
Enzon Pharmaceuticals
Market Cap: US$5.9m
Does not have significant operations.
ENZN
US$0.08
7D
6.7%
1Y
-34.3%
Harvard Apparatus Regenerative Technology
Market Cap: US$34.2m
A clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.
HRGN
US$1.99
7D
6.4%
1Y
-64.0%
Autolus Therapeutics
Market Cap: US$359.3m
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
AUTL
US$1.56
7D
22.8%
1Y
-54.8%
Spero Therapeutics
Market Cap: US$113.1m
A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
SPRO
US$1.97
7D
3.7%
1Y
53.9%
Anixa Biosciences
Market Cap: US$112.6m
A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
ANIX
US$3.44
7D
2.7%
1Y
9.2%
CytoMed Therapeutics
Market Cap: US$23.7m
A pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
GDTC
US$2.03
7D
8.0%
1Y
38.1%